Jenburkt Pharmaceuticals Q2 Results FY27: PAT Edges Up 0.49% To Rs 10.21 Cr, Revenue Rs 48.32 Cr, PAT Rs 10.21 Cr

Jenburkt Pharmaceuticals Ltd (JENBURPH) Q2 Results FY27 announced on 3 November 2026, covering the company's financial performance for the July to September quarter. The results date is 3 November, and the company reported revenue of Rs 48.32 Cr and net profit of Rs 10.21 Cr. Jenburkt Pharmaceuticals Q2 Results FY27 therefore describe a steady top line and an almost unchanged bottom line.

The Jenburkt Pharmaceuticals Q2 Results results analysis that follows covers the financial highlights, the listed business factors, the FY27 outlook and the risks, built on figures that Univest compiled for the quarter. The Financial Highlights table comes straight after this introduction and anchors every comparison.

Click Here – Get Free Investment Predictions

Jenburkt Pharmaceuticals Q2 Results FY27: Financial Highlights

Metric	Q2 FY27 (Sep 26)	Q2 FY26 (Sep 25)	YoY Change
Revenue	Rs 48.32 Cr	Rs 45.56 Cr	+6.06% YoY
Net Profit (PAT)	Rs 10.21 Cr	Rs 10.16 Cr	+0.49% YoY

Source: company filing for Jenburkt Pharmaceuticals Q2 Results FY27, 3 November 2026. Figures in Rs Crore.

Key Takeaways from Jenburkt Pharmaceuticals Q2 Results: What Stands Out

• Revenue of Rs 48.32 Cr is 6.06% above the Rs 45.56 Cr booked in the corresponding quarter of the previous year.
• Net profit of Rs 10.21 Cr compares with Rs 10.16 Cr a year ago, a rise of only 0.49% on the same base.
• Return on equity of 18.84% and return on capital employed of 25.34% in FY26 give Jenburkt Pharmaceuticals Q2 Results FY27 an annual backdrop.
• Net profit margin of 21.1% is lower than the 22.3% of the comparison quarter, which is the cost of slower profit growth.
• The performance analysis next shows how the two growth rates differ.

Jenburkt Pharmaceuticals Q2 Results FY27: Performance Analysis

Jenburkt Pharmaceuticals recorded revenue of Rs 48.32 Cr for July to September 2026, a gain of 6.06% over Rs 45.56 Cr in the year-earlier quarter. Net profit finished at Rs 10.21 Cr, up from Rs 10.16 Cr.

In this results analysis of Jenburkt Pharmaceuticals Q2 Results FY27, the contrast between growth rates is the main point. Sales rose by Rs 2.76 Cr while net profit rose by Rs 0.05 Cr, so the quarterly results show that nearly all of the extra revenue was absorbed before it reached the bottom line.

Followers of Jenburkt Pharmaceuticals Q2 Results will watch later filings to see whether profit growth catches up with sales, since a 0.49% rise in net profit is small beside 6.06% in revenue. The data records what changed, not the reason, so the results analysis turns to the business factors on record.

Check the Univest Screener for live results data

Key Business Factors This Quarter

Revenue Growth – The results analysis starts with sales, which grew 6.1% year on year to Rs 48.32 Cr in the latest quarter and are the faster-growing line of Jenburkt Pharmaceuticals Q2 Results FY27.

Net Profit Edge – Net profit rose 0.5% year on year to Rs 10.21 Cr, so the quarterly results show profit holding just above the year-earlier level rather than falling away. The gap from Rs 10.16 Cr to Rs 10.21 Cr is small, and it is worth reading in that light.

Annual Returns – Return on equity was 18.84% and return on capital employed was 25.34% in FY26, which together describe how efficiently shareholders' funds and total capital produced profit over the last full year.

FY27 Outlook After Jenburkt Pharmaceuticals Q2 Results

No management guidance is attached to these figures, so the FY27 picture depends on the quarters yet to be reported. The results analysis reads net profit of Rs 10.21 Cr as a single data point, to be tested against later filings and the sector conditions that companies disclose.

The next filing will show whether the pattern in Jenburkt Pharmaceuticals Q2 Results FY27, with revenue rising faster than profit, continues or changes. Until then, the sales base of Rs 48.32 Cr is the scale reference, and the narrower margin leads directly into the risks, where the supplied data lists three points to watch. Each of them is an annual or margin measure, so they add context to the Rs 10.21 Cr of net profit without changing what was reported for the quarter.

Key Risks to Watch After Jenburkt Pharmaceuticals Q2 Results FY27

Narrower Net Profit Margin

Net profit margin narrowed to 21.1% from 22.3% in the comparison quarter. That is a direct result of profit growing 0.49% while revenue grew 6.06%, and it is the first risk signal in the latest numbers.

Lower Return on Equity

Return on equity declined to 18.84% in FY26 from 20.25% in FY25. After Jenburkt Pharmaceuticals Q2 Results FY27, this annual fall sits beside the quarter's small YoY growth in profit as a second point to monitor.

Lower Return on Capital Employed

Return on capital employed declined to 25.34% in FY26 from 27.85% in FY25. The ratio remains well above the equity return, but the direction of change over the year is downward, and the quarter's profit growth does not by itself reverse it.

Download the Univest iOS App or Univest Android App to track quarterly results as they are declared.

Conclusion

Jenburkt Pharmaceuticals Q2 Results FY27 show revenue of Rs 48.32 Cr, up 6.06% YoY, and net profit of Rs 10.21 Cr, up 0.49%. These quarterly results are positive in direction but unequal in size, with each figure compared against the same quarter of last year and the margin moving from 22.3% to 21.1%, which is the arithmetic link between the 6.06% rise in sales and the 0.49% rise in profit. Readers of Jenburkt Pharmaceuticals Q2 Results can use the Univest Screener to explore other companies, and should consult a SEBI-registered advisor before acting.

Frequently Asked Questions on Jenburkt Pharmaceuticals Q2 Results FY27

What are Jenburkt Pharmaceuticals Q2 Results FY27?

Ans. Jenburkt Pharmaceuticals Q2 Results FY27 cover July to September 2026, with revenue of Rs 48.32 Cr and net profit of Rs 10.21 Cr, while the Financial Highlights table sets out each reported line.

What is the results date for Jenburkt Pharmaceuticals Q2 Results FY27?

Ans. Jenburkt Pharmaceuticals declared its Q2 FY27 results on 3 November 2026, so every comparison in this article rests on that filing date, as the opening paragraphs explain.

What revenue was reported in Jenburkt Pharmaceuticals Q2 Results FY27?

Ans. Jenburkt Pharmaceuticals reported revenue of Rs 48.32 Cr, compared with Rs 45.56 Cr a year earlier, which the Performance Analysis section sets beside the much smaller profit gain.

What net profit was reported in Jenburkt Pharmaceuticals Q2 Results FY27?

Ans. Jenburkt Pharmaceuticals reported net profit of Rs 10.21 Cr, compared with Rs 10.16 Cr a year earlier, which is why the Key Takeaways section calls the rise small.

How much YoY growth did revenue show in Jenburkt Pharmaceuticals Q2 Results FY27?

Ans. Revenue showed YoY growth of 6.06%, rising from Rs 45.56 Cr to Rs 48.32 Cr, while net profit grew only 0.49%, as the Performance Analysis section explains.

Did net profit rise or fall in Jenburkt Pharmaceuticals Q2 Results?

Ans. Net profit rose 0.49% to Rs 10.21 Cr from Rs 10.16 Cr, so profit edged higher while revenue grew faster, as the second Key Takeaways point records.

What was the net profit margin in Jenburkt Pharmaceuticals Q2 Results FY27?

Ans. Net profit margin narrowed to 21.1% from 22.3% in the comparison quarter, which means the Key Risks section treats the thinner margin as its first point to watch.

What returns did the company report in Jenburkt Pharmaceuticals Q2 Results?

Ans. Return on equity was 18.84% and return on capital employed was 25.34% in FY26, both lower than FY25, so the Key Business Factors section gives them as the annual context.

What business factors shaped Jenburkt Pharmaceuticals Q2 Results FY27?

Ans. The factors on record are 6.1% YoY revenue growth, a 0.5% rise in net profit and FY26 returns of 18.84% and 25.34%, all covered in the Key Business Factors section.

What are the key risks after Jenburkt Pharmaceuticals Q2 Results FY27?

Ans. The risks are a margin that narrowed to 21.1% and lower returns on equity and capital employed in FY26, each of which the Key Risks section explains in turn.

What is the outlook after Jenburkt Pharmaceuticals Q2 Results?

Ans. No management guidance accompanies the quarter, so the FY27 outlook depends on later quarters and disclosed sector conditions, as the Outlook section explains with reference to the Rs 10.21 Cr net profit.

Where can I find the complete Jenburkt Pharmaceuticals Q2 Results FY27 data?

Ans. The full figures are in the Financial Highlights table of this article and in the Univest Screener, which lists Jenburkt Pharmaceuticals beside other companies that have declared quarterly results.